Serologic assays for detection of antibodies against SARS?CoV?2 were developed quickly following onset of the pandemic in early 2020. These assays remain quite diverse in their format and design. Increasingly, manufacturers are developing quantitative assays to detect IgG or total binding antibodies to component(s) of the SARS?CoV?2 spike glycoprotein.
Despite the wide availability of these assays, one lingering question that remains is the clinical utility of these methods: when, how, and for what should they be used?
Download this new chapter, a part of the online clinical microbiology tool ClinMicroNow, now to learn more about SARS-CoV-2 serologic testing, courtesy of Wiley.
